Definium Therapeutics News - August 2026
🟢 Definium Therapeutics is trading 4.03% up today after positive Phase 3 Voyage results
Definium Therapeutics is trading 4.03% up now at $44.52 after positive Phase 3 Voyage results announced August 12, 2026. - The DT120 ODT study met its primary...
🟢 Definium Therapeutics is trading 8% up today after positive Phase 3 Voyage anxiety results
Definium Therapeutics is trading at $44.22 (+8.09%) after positive Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder. - The study met its...
DFTX Reports Positive Phase 3 Results for DT120 in Generalized Anxiety Disorder Study
Definium Therapeutics announced positive topline results from its Phase 3 Voyage study evaluating DT120 ODT for the treatment of generalized anxiety disorder...
Definium's Anxiety Drug Aces Its Final Trial — But Can a Single Win Justify a $50 Stock Price?
Shares of Definium Therapeutics surged 22.2% to $50.00 after the company announced its Voyage Phase 3 trial for generalized anxiety disorder hit its primary...
🟢 Definium Therapeutics is trading 22.22% up in pre-market after Voyage Phase 3 met primary endpoint
Definium Therapeutics is trading at $50.00 (+22.22%) after Voyage Phase 3 met its primary endpoint in generalized anxiety disorder. - DT120 ODT delivered a...